Published in Frontiers in Veterinary Research, the Feasibility of Long-Term Drug Delivery 
of the GLP-1 Exenatide is Demonstrated 
in this Study Conducted in Cats

MUMS Designation Places OKV-1001 on an Accelerated Conditional Approval Pathway and Demonstrates That the FDA Considers OKV-1001 To Be an Innovative Product That Addresses High Unmet Medical Need